This session will provide insight into outcomes for assessment of early lung disease in cystic fibrosis. It will highlight those outcomes with greatest potential for use in early intervention trials, those best for detecting early disease and those suited to monitoring progress. As knowledge about the nature of early lung disease accumulates, this information is crucial if we are to intervene to prevent the early onset and progression of lung disease in CF.
Describe how lung structure assessed by chest CT, MRI or other technologies can be used as outcome measures.
Appraise the role of preschool lung function in clinical practice and intervention studies
Summarize the application of new technologies to identify metabolite and infectious biomarkers of early lung disease